EQT Life Sciences and Nextech Invest led a €128m round in Tubulis.

EQT Life Sciences, a venture capital firm, and Nextech Invest, a venture capital and private equity firm, led a €128m round in Tubulis, a biotechnology company, with participation from Frazier Life Sciences, Deep Track Capital, Andera Partners, BioMedPartners, Fund+, Bayern Kapital, Evotec, coparion, Seventure Partners, OCCIDENT and High-Tech Gründerfonds. “This substantial financing from a syndicate of global specialist biotech investors recognizes Tubulis’ unique position in the ADC space. Our proprietary platform technologies and internal know-how are the foundation for our pipeline of truly differentiated protein-drug conjugates. Our goal is to establish Tubulis as a global ADC leader as we transition into a clinical-stage company and harness the full power of ADCs to bring their therapeutic value to patients with solid tumors,” Dominik Schumacher, Tubulis CEO and Co-Founder.